The Right Drug
The Right Dose
Right from the Start
Adverse Drug Reactions (ADRs) are the most expensive and clinically significant drug-related issue in long-term care settings today5.
The average facility – with 105 beds – experiences 135+ ADRs annually5, costing tens of thousands of dollars.
ADRs demand more staff hours, hiking labor costs and, because most facilities bill on a fixed monthly rate, this added cost is squeezed out of the facility’s already-strained bottom line.
Medicare and Medicaid* now cover a non-invasive, genetic test that reduces the risk of ADRs.
With a simple cheek swab, doctors can learn in advance if a drug is more likely to help or harm a patient- before he/she even consumes a drug.
Without PGx testing, doctors must put their patients through risky drug trials, costing facilities significant amounts of money – while subjecting their patients to ineffective medications and unintended side effects before finally finding a drug that works best.
Remarkably, most physicians are not up to speed with this innovative technology and unwittingly dismiss the test as a time constraint, at the patient’s and facility’s expense – thus, many people needlessly suffer from preventable ADRs.
It is a long established fact that a reader will be distracted by the readable content of a page.